Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 12-Month Low – Here’s Why

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $23.00 and last traded at $23.4660, with a volume of 2343587 shares traded. The stock had previously closed at $45.49.

Wall Street Analyst Weigh In

Several analysts have recently commented on AGIO shares. Bank of America reduced their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research upgraded Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and set a $56.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Finally, Scotiabank reduced their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Trading Down 45.7%

The firm has a market cap of $1.44 billion, a PE ratio of -3.45 and a beta of 0.89. The company has a 50 day moving average price of $40.64 and a 200 day moving average price of $37.01.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. During the same period in the previous year, the business earned $16.22 earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 43.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Theodore James Jr. Washburn sold 8,546 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the transaction, the insider owned 868 shares in the company, valued at approximately $32,003.16. This trade represents a 90.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Cecilia Jones sold 3,651 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the transaction, the chief financial officer directly owned 33,870 shares in the company, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 16,099 shares of company stock valued at $620,092 in the last three months. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of AGIO. Creative Planning lifted its stake in Agios Pharmaceuticals by 2.2% during the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 280 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 320 shares during the period. PNC Financial Services Group Inc. grew its holdings in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 499 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Agios Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after purchasing an additional 512 shares during the period. Finally, Nordea Investment Management AB raised its position in shares of Agios Pharmaceuticals by 0.3% during the 2nd quarter. Nordea Investment Management AB now owns 224,746 shares of the biopharmaceutical company’s stock worth $7,520,000 after buying an additional 573 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.